Comments
Loading...
Statera BioPharma Analyst Ratings and Price Targets | OTC:STAB | Benzinga
Statera BioPharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Statera BioPharma Corp from these most-recent analyst ratings.
Analyst Ratings for Statera BioPharma
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Statera BioPharma (STAB) stock?
There is no price target for Statera BioPharma
What is the most recent analyst rating for Statera BioPharma (STAB)?
There is no analyst for Statera BioPharma
When was the last upgrade for Statera BioPharma (STAB)?
There is no last upgrade for Statera BioPharma
When was the last downgrade for Statera BioPharma (STAB)?
There is no last downgrade for Statera BioPharma.
When is the next analyst rating going to be posted or updated for Statera BioPharma (STAB)?
There is no next analyst rating for Statera BioPharma.
Is the Analyst Rating Statera BioPharma (STAB) correct?
There is no next analyst rating for Statera BioPharma.
Browse analyst ratings and price targets on all stocks.